Arete Wealth Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $174K | Sell |
19,450
-750
| -4% | -$6.71K | 0.01% | 695 |
|
|
2025
Q1 | $152K | Hold |
20,200
| – | – | 0.01% | 686 |
|
|
2024
Q4 | $152K | Buy |
20,200
+8,150
| +68% | +$61.3K | 0.01% | 711 |
|
|
2024
Q3 | $92K | Sell |
12,050
-10,150
| -46% | -$77.5K | 0.01% | 675 |
|
|
2024
Q2 | $137K | Buy |
+22,200
| New | +$137K | 0.01% | 681 |
|
|
2024
Q1 | – | Sell |
-22,550
| Closed | -$135K | – | 412 |
|
|
2023
Q4 | $135K | Sell |
22,550
-750
| -3% | -$4.49K | 0.01% | 699 |
|
|
2023
Q3 | $165K | Buy |
23,300
+9,150
| +65% | +$64.8K | 0.03% | 446 |
|
|
2023
Q2 | $100K | Sell |
14,150
-9,823
| -41% | -$69.4K | 0.01% | 631 |
|
|
2023
Q1 | $200K | Buy |
23,973
+350
| +1% | +$2.92K | 0.02% | 580 |
|
|
2022
Q4 | $271M | Buy |
+23,623
| New | +$271M | 0.02% | 484 |
|